1.
Radiother Oncol
; 84(3): 252-6, 2007 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17720266
RESUMO
We treated 36 cases of stage I/II non-small cell lung cancer in inoperable patients. Treatments were planned to a total isocenter dose of 60Gy (8x7.5Gy) based on a dynamic field shaping arc, employing one arc to span as much area as possible and if needed additional weighted segments. The 2 year infield progression free probability is 65%. Disease-specific survival is 75% at 2 years. No patients experienced grade 3-4 toxicity.